Early N-terminal pro-brain natriuretic peptide measurements predict clinically significant ductus arteriosus in preterm infants

Acta Paediatrica, International Journal of Paediatrics

Volumn 98, Issue 8, 2009, Pages 1254-1259

  Ramakrishnan, S ^a   Heung, Y M ^a   Round, J ^b   Morris, T P ^c   Collinson, P ^a   Williams, A F ^b  

^a ST GEORGE S HOSPITAL   (United Kingdom)

^b ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^c MRC CLINICAL TRIALS UNIT   (United Kingdom)

Author keywords

Brain natriuretic peptide; Natriuretic peptides; Patent ductus arteriosus; Preterm

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE;

ARTICLE; BIRTH WEIGHT; BLOOD SAMPLING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC VALUE; DUCTUS ARTERIOSUS OBLITERATION; ECHOCARDIOGRAPHY; GESTATIONAL AGE; HUMAN; INFANT; MAJOR CLINICAL STUDY; PATENT DUCTUS ARTERIOSUS; PREMATURITY; PRIORITY JOURNAL; PROTEIN DETERMINATION; ROC CURVE; SENSITIVITY AND SPECIFICITY; SINGLE BLIND PROCEDURE;

BIOLOGICAL MARKERS; DUCTUS ARTERIOSUS, PATENT; ECHOCARDIOGRAPHY; HUMANS; INFANT, NEWBORN; INFANT, PREMATURE; INFANT, PREMATURE, DISEASES; NATRIURETIC PEPTIDE, BRAIN; PEPTIDE FRAGMENTS; PROSPECTIVE STUDIES; REFERENCE VALUES; ROC CURVE; SENSITIVITY AND SPECIFICITY; SINGLE-BLIND METHOD;

EID: 68249115965     PISSN: 08035253     EISSN: 16512227     Source Type: Journal    
DOI: 10.1111/j.1651-2227.2009.01315.x     Document Type: Article

References (23)

1. Rojas MA, Gonzalez A, Bancalari E, Claure N, Poole C, Silva-Neto G. Changing trends in the epidemiology and pathogenesis of neonatal chronic lung disease. J Pediatr 1995 126 : 605 10.
2. Dollberg S, Lusky A, Reichman B. Patent ductus arteriosus, indomethacin and necrotizing enterocolitis in very low birth weight infants: a population-based study. J Pediatr Gastroenterol Nutr 2005 40 : 184 8.
3. Costeloe K, Hennessy E, Gibson AT, Marlow N, Wilkinson AR. The EPICure study: outcomes to discharge from hospital for infants born at the threshold of viability. Pediatrics 2000 106 : 659 71.
4. Puddy VF, Amirmansour C, Williams AF, Singer DR. Plasma brain natriuretic peptide as a predictor of haemodynamically significant patent ductus arteriosus in preterm infants. Clin Sci (Lond) 2002 103 : 75 7.
5. da Graca RL, Hassinger DC, Flynn PA, Sison CP, Nesin M, Auld PA. Longitudinal changes of brain-type natriuretic peptide in preterm neonates. Pediatrics 2006 117 : 2183 9.
6. Flynn PA, da Graca RL, Auld PA, Nesin M, Kleinman CS. The use of a bedside assay for plasma B-type natriuretic peptide as a biomarker in the management of patent ductus arteriosus in premature neonates. J Pediatr 2005 147 : 38 42. (Pubitemid 40981143)
7. Choi BM, Lee KH, Eun BL, Yoo KH, Hong YS, Son CS, et al. Utility of rapid B-type natriuretic peptide assay for diagnosis of symptomatic patent ductus arteriosus in preterm infants. Pediatrics 2005 115 : e255 61.
8. Barnes SC, Collinson PO, Galasko G, Lahiri A, Senior R. Evaluation of N-terminal pro-B type natriuretic peptide analysis on the Elecsys 1010 and 2010 analysers. Ann Clin Biochem 2004 41 : 459 63.
9. Silverman NH, Lewis AB, Heymann MA, Rudolph AM. Echocardiographic assessment of ductus arteriosus shunt in premature infants. Circulation 1974 50 : 821 5.
10. Kluckow M, Evans N. Early echocardiographic prediction of symptomatic patent ductus arteriosus in preterm infants undergoing mechanical ventilation. J Pediatr 1995 127 : 774 9.
11. Zweig MH, Campbell G. Receiver-operating characteristic ROC) plots: a fundamental evaluation tool in clinical medicine. Clin Chem 1993 39 : 561 77.
12. McNamara PJ, Sehgal A. Towards rational management of the patent ductus arteriosus: the need for disease staging. Arch Dis Child Fetal Neonatal Ed 2007 92 : F424 7.
13. Schwartz D, Lellouch J. Explanatory and pragmatic attitudes in therapeutical trials. J Chronic Dis 1967 20 : 637 48.
14. Doust JA, Pietrzak E, Dobson A, Glasziou P. How well does B-type natriuretic peptide predict death and cardiac events in patients with heart failure: systematic review. BMJ 2005 330 : 625-34.
15. Ootaki Y, Yamaguchi M, Yoshimura N, Oka S, Yoshida M, Hasegawa T. Secretion of A-type and B-type natriuretic peptides into the bloodstream and pericardial space in children with congenital heart disease. J Thorac Cardiovasc Surg 2003 126 : 1411 16.
16. Holmstrom H, Hall C, Thaulow E. Plasma levels of natriuretic peptides and hemodynamic assessment of patent ductus arteriosus in preterm infants. Acta Paediatr 2001 90 : 184 91.
17. Sanjeev S, Pettersen M, Lua J, Thomas R, Shankaran S, L'Ecuyer T. Role of plasma B-type natriuretic peptide in screening for hemodynamically significant patent ductus arteriosus in preterm neonates. J Perinatol 2005 25 : 709 13.
18. Attridge JT, Kaufman D, Lim DS. B-type natriuretic peptide to guide therapy of patent ductus arteriosus. Arch Dis Child Fetal Neonatal Ed 2009 94 : F178 82.
19. Czernik C, Lemmer J, Metze B, Koehne PS, Mueller C, Obladen M. B-type natriuretic peptide to predict ductus intervention in infants <28 weeks. Pediatr Res 2008 64 : 286 90.
20. Kroll MH, Srisawasdi P. The clearance of BNP modeled using the NT-proBNP-BNP relationship. Biosystems 2007 88 : 147 55.
21. El Khuffash AF, Amoruso M, Culliton M, Molloy EJ. N-terminal pro-B-type natriuretic peptide as a marker of ductal haemodynamic significance in preterm infants: a prospective observational study. Arch Dis Child Fetal Neonatal Ed 2007 92 : F421 2.
22. Farombi-Oghuvbu I, Matthews T, Mayne PD, Guerin H, Corcoran JD. N-terminal pro-B-type natriuretic peptide: a measure of significant patent ductus arteriosus. Arch Dis Child Fetal Neonatal Ed 2008 93 : F257 60.
23. Nuntnarumit P, Khositseth A, Thanomsingh P. N-terminal probrain natriuretic peptide and patent ductus arteriosus in preterm infants. J Perinatol 2009 29 : 137 42.